gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Purinergic receptor P2Y, G-protein coupled, 13

P2Y13, GPR86
The product of this gene belongs to the family of G-protein coupled receptors. This family has several receptor subtypes with different pharmacological selectivity, which overlaps in some cases, for various adenosine and uridine nucleotides. This receptor is activated by ADP. [provided by RefSeq, Sep 2008] (from NCBI)
Top mentioned proteins: P2Y, P2Y12, V1a, P2Y2, HAD
Papers on P2Y13
P2X3 purinergic receptor overexpression is associated with poor recurrence-free survival in hepatocellular carcinoma patients.
New
Thevananther et al., Houston, United States. In Oncotarget, Jan 2016
High P2X3 purinergic receptor expression is associated with poor recurrence-free survival (RFS), while high P2Y13 expression is associated with improved RFS.
Pharmacology and structure of P2Y receptors.
Review
New
Hoffmann et al., Bonn, Germany. In Neuropharmacology, Nov 2015
There are eight mammalian P2Y receptor subtypes (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14).
Nucleotides Acting at P2Y Receptors: Connecting Structure and Function.
Review
New
Kiselev et al., Equatorial Guinea. In Mol Pharmacol, Aug 2015
The human P2YRs are fully activated by ATP (P2Y2 and P2Y11), ADP (P2Y1, P2Y12, and P2Y13), UTP (P2Y2 and P2Y4), UDP (P2Y6 and P2Y14), and UDP glucose (P2Y14).
Increased atherosclerosis in P2Y13/apolipoprotein E double-knockout mice: contribution of P2Y13 to reverse cholesterol transport.
New
Martinez et al., Toulouse, France. In Cardiovasc Res, Jun 2015
Hepatic uptake of HDL holoparticles involves the P2Y13 receptor, independently of the selective cholesteryl ester uptake mediated by scavenger receptor class B, type I (SR-BI).
The involvement of P2Y12 receptors, NADPH oxidase, and lipid rafts in the action of extracellular ATP on synaptic transmission at the frog neuromuscular junction.
New
Giniatullin et al., Kazan', Russia. In Neuroscience, Mar 2015
Using subtype-specific antagonists, we found that the P2Y13 blocker 2-[(2-chloro-5-nitrophenyl)azo]-5-hydroxy-6-methyl-3-[(phosphonooxy)methyl]-4-pyridinecarboxaldehyde did not prevent the depressant action of ATP.
RhoA/ROCK pathway mediates p38 MAPK activation and morphological changes downstream of P2Y12/13 receptors in spinal microglia in neuropathic pain.
New
Noguchi et al., Nishinomiya, Japan. In Glia, Feb 2015
Recent studies have indicated an important role of ATP receptors in spinal microglia, such as P2Y12 or P2Y13, in the development of chronic pain.
Ecto-F1-ATPase/P2Y pathways in metabolic and vascular functions of high density lipoproteins.
Review
Lichtenstein et al., Toulouse, France. In Atherosclerosis, 2015
On hepatocytes, the ecto-F1-ATPase is coupled to P2Y13 receptor and contributes to HDL holoparticle endocytosis.
Autocrine Regulation of UVA-Induced IL-6 Production via Release of ATP and Activation of P2Y Receptors.
Sakamoto et al., Tokyo, Japan. In Plos One, 2014
IL-6 production was increased after UVA irradiation, and this increase was inhibited by ecto-nucleotidase or by antagonists of P2Y11 or P2Y13 receptor.
Neuroprotection Mediated by P2Y13 Nucleotide Receptors in Neurons.
Review
Miras-Portugal et al., Madrid, Spain. In Comput Struct Biotechnol J, 2014
ADP-specific P2Y13 receptor constitutes one of the most recently identified nucleotide receptor and the understanding of their physiological role is currently under investigation.
ADP-induced bladder contractility is mediated by P2Y12 receptor and temporally regulated by ectonucleotidases and adenosine signaling.
Hill et al., Boston, United States. In Faseb J, 2014
Here, we demonstrate, using myography, that ADP and ADPβS dose-dependently induce mouse BSM contraction, and ADP-induced BSM contraction is blocked by a selective P2Y12 receptor (P2Y12R) antagonist, PSB 0739 (25 μM), but is unaffected by P2Y1 and P2Y13 receptor antagonists.
P2Y13 receptor-mediated rapid increase in intracellular calcium induced by ADP in cultured dorsal spinal cord microglia.
Chen et al., Zunyi, China. In Neurochem Res, 2014
The action of ADP on [Ca(2+)]i was significantly blocked by MRS2211 (a selective P2Y13 receptor antagonist), but was unaffected by MRS2179 (a selective P2Y1 receptor antagonist) or MRS2395 (a selective P2Y12 receptor antagonist), which suggest that P2Y13 receptor may be responsible for ADP-evoked Ca(2+) mobilization in cultured microglia.
Nucleolin down-regulation is involved in ADP-induced cell cycle arrest in S phase and cell apoptosis in vascular endothelial cells.
Hu et al., Changsha, China. In Plos One, 2013
HUVEC and HAEC expressed ADP receptor P2Y13 receptor, but did not express P2Y1 or P2Y12 receptors.
Expression and characterization of purinergic receptors in rat middle meningeal artery-potential role in migraine.
Edvinsson et al., Glostrup, Denmark. In Plos One, 2013
P2X1 and P2Y6 receptors are the strongest contractile receptors and, surprisingly, ADPβS caused contraction most likely via P2Y1 or P2Y13 receptors, which is not observed in other arteries.
Expression of ATP receptors in the rat dorsal root ganglion and spinal cord.
Review
Noguchi et al., Nishinomiya, Japan. In Anat Sci Int, 2013
Currently, seven P2X receptors (P2X1-7) and eight P2Y receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14) are recognized.
Coupling of P2Y receptors to G proteins and other signaling pathways.
Weisman et al., Columbia, United States. In Wiley Interdiscip Rev Membr Transp Signal, 2012
There are eight subtypes of P2Y receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14), which activate intracellular signaling cascades to regulate a variety of cellular processes, including proliferation, differentiation, phagocytosis, secretion, nociception, cell adhesion, and cell migration.
Involvement of P2Y13 receptor in suppression of neuronal differentiation.
GeneRIF
Kojima et al., Noda, Japan. In Neurosci Lett, 2012
P2Y13 receptor in invloves in suppression of neuronal differentiation. P2Y13 receptor antagonists might be candidates for treatment of neurodegenerative diseases.
Reduced bone turnover in mice lacking the P2Y13 receptor of ADP.
GeneRIF
Gartland et al., Sheffield, United Kingdom. In Mol Endocrinol, 2012
study to examine the role of P2Y13 receptor in bone homeostasis both in vivo and in vitro; deletion of the P2Y13 receptor leads to less trabecular bone in mice, by affecting both osteoblasts and osteoclasts
Altered lipoprotein metabolism in P2Y(13) knockout mice.
GeneRIF
Puig et al., Rahway, United States. In Biochim Biophys Acta, 2010
experiments assess a role for the purinergic receptor P2Y(13) in the regulation of lipoprotein metabolism and demonstrate that modulating its activity could be of benefit to the treatment of dyslipidemia in people
P2Y13 receptor is critical for reverse cholesterol transport.
GeneRIF
Martinez et al., Toulouse, France. In Hepatology, 2010
study shows P2Y(13)-deficient mice exhibited a decrease in hepatic HDL cholesterol uptake, hepatic cholesterol content, and biliary cholesterol output, data indicate P2Y13 activity is involved in macrophage-to-feces reverse cholesterol transport
The purinergic P2Y(13) receptor activates the Nrf2/HO-1 axis and protects against oxidative stress-induced neuronal death.
GeneRIF
Cuadrado et al., Madrid, Spain. In Free Radic Biol Med, 2010
results show a previously unrecognized role of the purinergic P2Y13 receptor in the induction of the Nrf2/HO-1 antioxidant response and in protection against oxidative stress
share on facebooktweetadd +1mail to friends